Pharmasset the stand out small cap performer in first quarter

Date April 04, 2011

Leading up to this month's International Liver Congress and the presentation of yet more impressive clinical data on its promising hepatitis C candidates, Pharmasset was the stand out performer from the small, micro and nano stocks during the first quarter. Shares closed at a record high of $78.71, valuing the New Jersey company with just phase II assets at a very impressive $2.9bn.

Other notable and perhaps surprising gainers were: Jazz Pharmaceuticals, Depomed, Pernix Therapeutics and KV Pharmaceutical, even after the latter's recent declines on the back of some damaging publicity. Meanwhile the largely predictable regulatory setbacks to Orexigen Therapeutics’ obesity candidate and MannKind’s inhaled insulin have left the companies assessing their next moves. And late stage clinical failures were particularly severe on Renovo, Inspire Pharmaceuticals and Xoma (see tables below).

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd